Streetbeat News

Regulatory

ZVSA

ZyVersa Therapeutics has announced the publication of an article in the peer-reviewed journal, Aging, which demonstrates that inflammasome NLRP3 activation is associated with an age-related decline in kidney health.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 11:13 am

MA

V

The Federal Reserve is planning to introduce a proposal to reduce the fees merchants pay to banks for debit card transactions. This could impact major card issuers like Mastercard (MA) and Visa (V), who have been charging a fee of 21 cents plus 0.05% of the total transaction value for each transaction. The Durbin amendment, which introduced this fee cap, has led to a shift in the payments sector, reducing the influence of networks like Visa and Mastercard in setting interchange fees.

Portfolio Pulse from Anusuya Lahiri

October 18, 2023 | 11:11 am

TNXP

Tonix Pharmaceuticals announced that a study published in the Journal Nature by Center for Transplantation Sciences Faculty, Massachusetts General Hospital and Egenesis, utilized TNX-1500 as part of immune modulating regimen to prevent organ transplant rejection.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 11:10 am

ASLN

ASLAN Pharmaceuticals is set to co-host a KOL panel discussion on changes in clinical trial and treatment landscape for Atopic Dermatitis on October 24, 2023.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 11:07 am

TLSA

The U.S. Food and Drug Administration (FDA) has approved at-home dosing of Intranasal Foralumab for multiple sclerosis patients. This decision was announced by Tiziana Life Sciences.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 11:02 am

NTLA

Intellia Therapeutics has received FDA clearance for its IND application to initiate a pivotal Phase 3 trial of NTLA-2001 for the treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 11:01 am

AAPL

MSFT

TSLA

Microsoft CEO Satya Nadella has expressed concerns about the potential dangers of artificial intelligence (AI) and called for guidance from moral philosophers and developers. He compared AI to cars and airplanes, which are regulated and used within well-defined laws, suggesting a need for AI regulation. Earlier this year, over 1000 tech experts, including Elon Musk and Steve Wozniak, signed an open letter calling for a pause in AI developments until safety protocols are created.

Portfolio Pulse from Rounak Jain

October 18, 2023 | 10:45 am

SAGE

The FDA has granted Orphan Drug Designation to Sage Therapeutics' SAGE-718 for Huntington's Disease. This designation is given to drugs that are intended to treat rare diseases, providing certain benefits to the drug developer.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 10:32 am

IMRN

Immuron Limited has commenced the second cohort of a clinical trial to evaluate the efficacy of Travelan for the prevention of infectious diarrhea caused by enterotoxigenic Escherichia coli. The study is being led by Dr Mohamed Al-Ibrahim at the Pharmaron CPC FDA inspected Clinical Research Facility Inpatient Unit in Baltimore, Maryland US.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 10:03 am

BCLI

BrainStorm Cell Therapeutics is set to meet with the US FDA to discuss the development plan for NurOwn, a treatment for ALS. The company is withdrawing its Biologics License Application (BLA) for NurOwn, a decision coordinated with and viewed by the FDA as a withdrawal without prejudice. BrainStorm remains committed to the ALS community and is exploring next steps for NurOwn, including publishing emerging clinical data and developing a protocol for an additional clinical study.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 10:03 am